?? Webinar Alert! Streamlining IND Submissions with AutoIND: How to Expedite Your Path to Clinical Trials ?? Date: Thursday, December 12, 2024 ?? Time: 11:00 AM - Noon PST ?? Where: Online Don’t miss this opportunity to dive into real-world case studies and discover how to submit INDs faster, more efficiently, and with greater confidence. Join Brandon Rice, Weave's Chief Product Officer, for an engaging session on how #AutoIND revolutionizes IND submissions with AI-powered automation. In this session, you will learn how AutoIND can: ? Accelerate Submissions: Speed up data organization, drafting, and end-to-end content management with automated document generation and iteration. ? Increase Accuracy: Minimize costly errors and revisions with intelligent validation tools. ? Streamline Collaboration:?Foster efficient teamwork across all stakeholders with centralized document management, unmatched user-level visibility and comprehensive communication tools. Who Should Join? ?? Regulatory Ops Professionals ?? Medical Writers ?? Pre-Clinical/Drug Dev Teams ?? Start-ups & Established Pharma Companies Reserve Your Spot Now at https://lnkd.in/gvCnbAjq #WebinarAlert #INDSubmissions #AIinHealthcare #RegulatoryOperations #MedicalWriting #RegulatoryCompliance
Weave
生物技术研究
Weave together thousands of pages of source documents and accelerate your IND submission
关于我们
Weave Bio is an AI-native, life sciences platform company that provides a technically robust, AI-enabled platform for major pain points inherent in the pharma and biotech industries. Our flagship product, AutoIND, is the first offering on Weave’s comprehensive Regulatory Automation and Lifecycle Management (ReALM) platform. With AutoIND we streamline the Investigational New Drug (IND) application process and enable drug development teams to build a living record of their therapeutic candidates, delivering significant improvements in both efficiency and quality. AutoIND automatically generates content based on users’ own source data, regulatory guidelines, and public information. The solution offers a robust, in-platform process for quality review and significantly enhances editing capabilities and oversight for teams. While conventional IND preparation processes can take more than a year, AutoIND can produce a first draft of an IND in a single day and reduce the overall time to generate a final IND submission by over 50%, returning capacity to regulatory teams, lowering costs, and ultimately accelerating the time it takes to get treatments to patients. For more information, visit weave.bio
- 网站
-
https://www.weave.bio/
Weave的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 类型
- 私人持股
- 创立
- 2023
Weave员工
-
Ari Caroline
Co-Founder & CEO @ Weave | Accelerating INDs at the speed of AI| First Chief Analytics Officer @ Memorial Sloan Kettering
-
Christine Aylward
-
Tammy L.
Experienced Field Marketing Manager | Driving Engagement and Revenue Through Strategic Campaign and Event Planning
-
?Wes Galliher, Ph.D.
Outcomes-Obsessed Product Leader in B2B SaaS | Using Customer Data Insights to Help My Teams Build the Right Products, Faster
动态
-
?? Collaborate smarter with #AutoIND from Weave! Drafting regulatory documents requires coordination across teams, precise wording & tone to create a singular voice, and the ability to track various user edits with confidence.? Whether you’re refining submission content or?capturing feedback across teams, Version History in AutoIND provideS the visibility and control you need to produce accurate, high-quality documents and maintain a seamless workflow.? ? Key Benefits of Version History: 1?? Comprehensive Tracking: See who made changes, what was edited + when, all in one place. 2?? Effortless Restoration: Preview and restore earlier versions to reverse undesired edits with ease. 3?? Reliable Backup: Rest assured every iteration of your content is securely backed.? ?? Ready to see more of AutoIND in action??Contact us for a demo today: [email protected] #WeaveWednesday #AutoIND #CollaborationTools #VersionControl #RegulatoryExcellence #INDsubmission
-
????Weave Bio Wins "BioTech AI Innovation of the Year" at the 2024 BioTech Breakthrough Awards! We’re thrilled to announce that #AutoIND has been named BioTech AI Innovation of the Year in the prestigious BioTech Breakthrough Awards! This recognition highlights our mission to transform drug development by automating and accelerating the IND process. AutoIND uses AI to streamline the preparation, writing, and review of Investigational New Drug (IND) applications, reducing manual effort and cutting submission time by over 50%. It’s a game-changer for biotech teams, enhancing collaboration, quality review, and speed to bring life-saving treatments to patients faster. ?? Why AutoIND? ?? Auto-generates IND drafts in just one day ?? Seamlessly integrates AI for content refinement ?? Organizes and tags source data for quick access ?? Cuts the time and cost of regulatory submissions We're proud to be recognized as a leader in AI-driven solutions for biotech and pharma—transforming how therapies are brought to market. Read the full release ????https://lnkd.in/gU9bPuNe #Biotech #AI #Innovation #WeaveBio #HealthTech #Awards #Regulatory
-
-
?? Exciting News! We're Growing! Weave is thrilled to welcome Julie Xu as our Sr. Product Manager! ?? With her extensive background in product roles at healthcare tech companies she will be instrumental in helping us create new offerings that help streamline the IND submission processes and accelerate time to market. Join us in giving a warm welcome to Julie! We are excited to see her ideas in action. ?? #WeaveBio #TeamGrowth #ProductManager #Biotech #Innovation
-
-
Weave转发了
happy #WeaveWednesday ! If you're interested in learning more about #AutoIND , dm me to set up a meeting!
?????Simplify your team’s QC, reduce manual errors, and speed up your submission process! In the fast-paced world of IND submissions, quality control is not just important—it’s essential. With #AutoIND, you can streamline the entire process, boost content quality and ensure precision and accuracy every step of the way. Our advanced data verification tools empower your team to quickly and confidently verify every detail in your submission so that you get it right the first time. ?? Key Features: ? Flagging for correction: Quickly identify discrepancies and flag for review or correction. ? Notes & follow-up: Capture notes on flagged items to make follow-up a breeze. ? Instant access to Source Data: Highlight a sentence, then click to trace back to original source content with ease. Ready to see it in action? Contact us for a demo today: [email protected] #INDReview #QualityControl #AutoIND #StreamlineYourProcess #Weavewednesday #Regulatory
-
?????Simplify your team’s QC, reduce manual errors, and speed up your submission process! In the fast-paced world of IND submissions, quality control is not just important—it’s essential. With #AutoIND, you can streamline the entire process, boost content quality and ensure precision and accuracy every step of the way. Our advanced data verification tools empower your team to quickly and confidently verify every detail in your submission so that you get it right the first time. ?? Key Features: ? Flagging for correction: Quickly identify discrepancies and flag for review or correction. ? Notes & follow-up: Capture notes on flagged items to make follow-up a breeze. ? Instant access to Source Data: Highlight a sentence, then click to trace back to original source content with ease. Ready to see it in action? Contact us for a demo today: [email protected] #INDReview #QualityControl #AutoIND #StreamlineYourProcess #Weavewednesday #Regulatory
-
We’re proud to be a Bronze Sponsor of the RAPS San Francisco Chapter event featuring Dr. Peter Marks! Excited to support this important conversation on FDA insights for 2025. Looking forward to an insightful session and connecting with industry leaders in San Francisco. ?? Don’t miss out on the Early Bird pricing—register today ?? https://lnkd.in/g9vszmmc
RAPS San Francisco Chapter is excited to kick off 2025 by featuring Peter Marks, M.D., Ph.D. from the FDA as the speaker at our first in-person event on January 12th in downtown San Francisco. Dr. Marks will be providing his thoughts and insights on what to expect from the FDA in the new year. We do expect the event to fully sell out, so please take advantage of Early Bird pricing that is valid for the next month until 12/14. Registration link is here: https://lnkd.in/g9vszmmc Thank you to our Gold Sponsors SGS and BioPhy, Silver Sponsor IPM Integrated Project Management Company and Qserve Group, Bronze Sponsor MyData-TRUST - Data Protection & Privacy for Life Sciences and Weave. #RAPS #regulatoryaffairs #FDA
-
?? The Next Era of Innovation is Here! ?? Science, technology, and research & development (R&D) are reshaping industries and driving global progress. From AI and biotechnology to sustainable energy and advanced manufacturing, the pace of innovation is accelerating—and the potential for positive change is limitless. This recent article from the World Economic Forum walks us through the key advancements to watch including: ?? AI & Automation: Revolutionizing industries, enabling smarter solutions, and accelerating R&D. ?? Sustainability: A focus on green technologies, sustainable practices, and climate resilience. ?? Biotech Breakthroughs: Advancing healthcare and drug development with cutting-edge research. ?? Digital Transformation: Reshaping how we connect, communicate, and collaborate globally. Weave is proud to contribute to this dynamic landscape. As we enter this new era of discovery, the importance of collaboration, investment, and a global mindset cannot be overstated. Together, we can solve the challenges of tomorrow—today. ?? ?? Read the full article from the World Economic Forum: https://lnkd.in/e867TQFK #Innovation #Technology #AI #R&D #HealthcareInnovation #AutoIND
-
?? Hey #Regulatory Affairs Professionals! ?? At Weave Bio, we’re deeply committed to understanding the real challenges you face in preparing IND submissions. We want to make sure we’re focusing on the right solutions—ones that truly make a difference in your day-to-day work. ??We’d love to hear directly from you as your input will guide us as we develop AI-powered tools designed to meet your needs. Together, we can shape the future of regulatory processes in biotech! #RegulatoryAffairs #INDSubmission #BiotechInnovation #AI #WeaveBio #Survey
此处无法显示此内容
在领英 APP 中访问此内容等
-
?? A big thanks to Umut Eser for sharing this important update on the FDA’s CDER Guidance changes for 2024! ?? With these updates, staying compliant can be a challenge, but it’s also an opportunity to streamline and accelerate the IND submission process. More and more biopharma companies are turning to AI-driven solutions like #AutoIND to reduce errors and speed up submissions—cutting down the time it takes to get critical therapies to market. ?? Thanks again, Umut Eser, for highlighting this important update! #AI #FDA #RegulatoryAffairs #BioPharma #Innovation #AutoIND
Co-Founder & Chief AI Officer @ Weave | Accelerating the IND application process at the speed of AI | PhD @ Stanford | Postdoc @ Harvard
The FDA’s CDER released a massive batch of guidance updates effective since the start of 2024: https://lnkd.in/ebB6Q64T It’s easy to see why so many biopharma are turning to auto-templating to keep up. Thankfully, with the current technology, it is possible to adapt to these changes, auto-updating prompts and streamlining the drafting and reviewing of IND applications. Staying current is challenging, but with AI, it’s manageable—and even efficient. Are you or your company leveraging AI for this kind of regulatory automation? Let's chat. I’d love to hear your thoughts! ?? #AI #FDA #regulatoryaffairs #biopharma #innovation #AutoIND
CDER 2024 Guidance Agenda New, Revised Draft and Immediately in Effect Guidances | January 2024
fda.gov